Biodesix preliminary Q3 revenue $10.6M-$11.2M, core lung diagnostics up 96-103% YoY

BIODESIX INC

2022-Q3 EPS reported -$1.22 revenue$28,605,000

Total Q3 2022 revenue estimated $10.6M-$11.2M, up 62-71% YoY.
Core lung diagnostic testing revenue $8.9M-$9.2M, a 96-103% increase YoY.
COVID testing revenue $1.1M-$1.3M, up 117-157% YoY; expects immaterial in Q4.
Biopharma services revenue $0.6M-$0.7M, down 53-60% YoY due to clinical study delays.
Cash and equivalents $15.2M as of Sep 30; expects FY2022 revenue near high end of $37.5M-$39.5M guidance range.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.